• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis.

作者信息

Deng Guofang, Fu Liang

机构信息

Pulmonary Diseases Department, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China; National Clinical Research Center for Infectious Disease (Shenzhen), Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis), Shenzhen Clinical Research Center for Tuberculosis, Shenzhen, China.

Pulmonary Diseases Department, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China; National Clinical Research Center for Infectious Disease (Shenzhen), Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis), Shenzhen Clinical Research Center for Tuberculosis, Shenzhen, China.

出版信息

Lancet Infect Dis. 2024 Sep;24(9):940-941. doi: 10.1016/S1473-3099(24)00257-3. Epub 2024 May 17.

DOI:10.1016/S1473-3099(24)00257-3
PMID:38768618
Abstract
摘要

相似文献

1
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis.用于药物敏感和耐药结核病的贝达喹啉、普瑞玛胺、莫西沙星和吡嗪酰胺治疗方案。
Lancet Infect Dis. 2024 Sep;24(9):940-941. doi: 10.1016/S1473-3099(24)00257-3. Epub 2024 May 17.
2
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response.欧洲用于耐利福平结核病的贝达喹啉、普瑞玛尼、利奈唑胺和莫西沙星（BPaL(M)）方案的药物供应及耐药性检测：作者回应
Clin Microbiol Infect. 2024 Sep;30(9):1207-1208. doi: 10.1016/j.cmi.2024.06.009. Epub 2024 Jun 18.
3
Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.贝达喹啉联合利奈唑胺或莫西沙星与吡嗪酰胺对鼠结核模型的新型方案的贡献。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.00021-19. Print 2019 May.
4
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.在抗结核治疗的前 8 周，莫西沙星、贝达喹啉（PA-824）和吡嗪酰胺联合使用的疗效和安全性：一项在药物敏感性或耐药性肺结核患者中进行的 2b 期、开放标签、部分随机试验。
Lancet. 2015 May 2;385(9979):1738-1747. doi: 10.1016/S0140-6736(14)62002-X. Epub 2015 Mar 18.
5
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.贝达喹啉-pretomanid-莫西沙星-吡嗪酰胺治疗敏感和耐药肺结核：一项 2c 期、开放标签、多中心、部分随机对照试验。
Lancet Infect Dis. 2024 Sep;24(9):1003-1014. doi: 10.1016/S1473-3099(24)00223-8. Epub 2024 May 17.
6
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis.贝达喹啉、普瑞马尼德以及利奈唑胺联合或不联合莫西沙星用于治疗结核病。
Lancet Respir Med. 2024 Feb;12(2):e5-e6. doi: 10.1016/S2213-2600(23)00426-5. Epub 2023 Nov 30.
7
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.在欧洲，利福平耐药结核病的贝达喹啉、普托马尼德、利奈唑胺和莫西沙星（BPaL（M））方案的药物供应和耐药检测情况。
Clin Microbiol Infect. 2024 Sep;30(9):1197.e1-1197.e4. doi: 10.1016/j.cmi.2024.03.009. Epub 2024 Mar 13.
8
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.硝基咪唑类药物PA - 824和TBA - 354对新型抗结核治疗方案在小鼠结核病模型中活性的贡献。
Antimicrob Agents Chemother. 2015 Jan;59(1):129-35. doi: 10.1128/AAC.03822-14. Epub 2014 Oct 20.
9
Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.在德国，将贝达喹啉纳入耐多药/广泛耐药结核病治疗方案的成本效益分析。
Eur Respir J. 2015 Dec;46(6):1826-9. doi: 10.1183/13993003.00811-2015. Epub 2015 Oct 22.
10
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.贝达喹啉、莫西沙星、普托马尼和吡嗪酰胺治疗药物敏感或耐药性肺结核患者的前 8 周：一项多中心、开放标签、部分随机、2b 期临床试验。
Lancet Respir Med. 2019 Dec;7(12):1048-1058. doi: 10.1016/S2213-2600(19)30366-2. Epub 2019 Nov 12.